{"entity":{"id":"nct05768529","kind":"trial","name":"Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","aka":[],"tldr":"A phase 1/2 trial of U16 in non-Hodgkin lymphoma, run by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, now recruiting.","summary":"Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05768529 by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, with 100 participants planned, started 2023-03-28 and due to reach its primary completion in 2024-12-31. Interventions recorded: U16.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05768529","url":"https://clinicaltrials.gov/study/NCT05768529"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05768529","phase":"1/2","setting":"A Single-arm, Open and Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of U16 Injection in the Treatment of Refractory/Recurrent B-cell Non-Hodgkin's Lymphoma (r/r B-NHL)","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","enrolled":100,"outcomes":[]},"route":"/trials/nct05768529/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}